- ►alfediam.org [PDF] JP Riveline, N Danchin, F Ledru, M Varroud- … - Diabetes and Metabolism, 2003 - Elsevier The main molecule studied is glibenclamide (GB). In vitro and in animal studies,
GB is both deleterious for ischemic preconditionning (IPC) and protective for
arrhythmia during acute ischemia. Glimepiride (GM) and gliclazide (GCZ) do ... Cited by 32 - Related articles - BL Direct - All 4 versions
SJ Hamilton, GT Chew, GF Watts - Diabetes & Vascular Disease Research, 2007 - dvr.sagepub.com Abstract E ndothelial dysfunction is universal in diabetes, being intimately
involved with the development of cardiovas- cular disease. The pathogenesis of
endothelial dys- function in diabetes is complex. It is initially related ... Cited by 17 - Related articles - BL Direct - All 6 versions
N Ihlemann, KH Stokholm, PC Eskildsen - Diabetic medicine, 2002 - pt.wkhealth.com Background: Type 2 diabetes is associated with an increased risk of
cardiovascular disease. Endothelial dysfunction is thought to be an early marker
of atherosclerosis. The purpose of this study was to assess whether ... Cited by 11 - Related articles - BL Direct - All 6 versions
AJ Krentz - International Congress Series, 2003 - Elsevier Sulfonylureas have been used extensively for the treatment of type 2 diabetes
since the 1950s. In general, the class has proved to be efficacious and well
tolerated [1]. Unwanted effects, notably risk of hypoglycemia and gain in ... Cited by 8 - Related articles - All 3 versions
TC Wascher, U Boes - Clinical Physiology and Functional Imaging, 2005 - interscience.wiley.com Sulphonylureas (SUs) act by inhibition of β-cell K ATP channels after binding
to the sulphonylurea receptor SUR1. K ATP channels are also expressed in cardiac
and vascular myocytes coupled to SUR2A and SUR2B involved into adaptations ... Cited by 4 - Related articles - All 4 versions
D Ravel, N Levens, M Félétou, G Néliat, J … - Fundam Clin Pharmacol, 2003 - interscience.wiley.com The potency of three sulphonylureas, glibenclamide, glimepiride and gliclazide
in antagonizing the vasorelaxant action of openers of adenosine triphosphate
(ATP)-regulated K + channel (K ATP ) was studied in vivo and in vitro in ... Cited by 4 - Related articles - All 4 versions
- ►ru.nl [PDF] RJ Legtenberg, RJF Houston, A Heerschap, B … - European journal of pharmacology, 2002 - Elsevier Previous research has shown that the sulfonylurea derivative glibenclamide may
improve post-ischemic cardiac functional recovery. Although K ATP channel
blockade is a possible explanation for this observation, alternative ... Cited by 2 - Related articles - All 5 versions
M Mohiuddin, ATMZ Azam, MS Amran, MA … - scialert.net J. Pharmacol. Toxicol, 2009 not expected in diabetic patients receiving oral
antidiabetic agents that are not metabolized through the CYP 3A4 system (eg,
tolbutamide, gliclazide, glibenclamide, glipizide and metformin) (Verspeelt ... Related articles - All 3 versions
R AVANCÉE, A Fredenrich, P Bayer - masson.fr La principale molécule étudiée est le glibenclamide (GB). In vitro et chez
l'animal le GB présente des effets ā la fois délétčres sur le
pré-conditionnement ischémique (PCI) et protecteurs sur les troubles du ... Related articles - Cached
